GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (FRA:4XC1) » Definitions » Quick Ratio

KalVista Pharmaceuticals (FRA:4XC1) Quick Ratio : 5.44 (As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. KalVista Pharmaceuticals's quick ratio for the quarter that ended in Jan. 2024 was 5.44.

KalVista Pharmaceuticals has a quick ratio of 5.44. It generally indicates good short-term financial strength.

The historical rank and industry rank for KalVista Pharmaceuticals's Quick Ratio or its related term are showing as below:

FRA:4XC1' s Quick Ratio Range Over the Past 10 Years
Min: 0.39   Med: 10.45   Max: 30.35
Current: 5.44

During the past 12 years, KalVista Pharmaceuticals's highest Quick Ratio was 30.35. The lowest was 0.39. And the median was 10.45.

FRA:4XC1's Quick Ratio is ranked better than
63.3% of 1545 companies
in the Biotechnology industry
Industry Median: 3.6 vs FRA:4XC1: 5.44

KalVista Pharmaceuticals Quick Ratio Historical Data

The historical data trend for KalVista Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Quick Ratio Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.40 11.49 27.04 16.73 11.46

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.56 11.46 10.60 7.25 5.44

Competitive Comparison of KalVista Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, KalVista Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Quick Ratio falls into.



KalVista Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

KalVista Pharmaceuticals's Quick Ratio for the fiscal year that ended in Apr. 2023 is calculated as

Quick Ratio (A: Apr. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(157.161-0)/13.709
=11.46

KalVista Pharmaceuticals's Quick Ratio for the quarter that ended in Jan. 2024 is calculated as

Quick Ratio (Q: Jan. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(95.567-0)/17.56
=5.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KalVista Pharmaceuticals  (FRA:4XC1) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


KalVista Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals (FRA:4XC1) Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (FRA:4XC1) Headlines

No Headlines